NCT04646395 2026-04-06Study of Acalabrutinib and Tafasitamab in MZL PatientsInternational Extranodal Lymphoma Study Group (IELSG)Phase 2 Active not recruiting26 enrolled
NCT04680052 2025-12-22InMINDIncyte CorporationPhase 3 Active not recruiting654 enrolled 40 charts 1 FDA